CORDIS
EU research results

CORDIS

English EN

Protein-excipient Interactions and Protein-Protein Interactions in formulation

Project information

Grant agreement ID: 675074

Status

Closed project

  • Start date

    1 January 2016

  • End date

    31 December 2019

Funded under:

H2020-EU.1.3.1.

  • Overall budget:

    € 4 067 745,48

  • EU contribution

    € 4 067 745,48

Coordinated by:

DANMARKS TEKNISKE UNIVERSITET

Denmark

Objective

The revolution of biotechnology has led to the creation of various types of therapeutic biologics with the potential to provide treatment for new chronic and malignant diseases. Though the potential advantages of biologics lay in their high specificity and potency combined with few side effects, their formulation still remains a large challenge to pharmaceutical scientists. This is in part due to the complex, not-well understood relationship between the physicochemical properties of proteins and formulation conditions required for protein stability. A comprehensive understanding of the molecular mechanisms behind protein stabilization and solubility would provide the formulation scientists with knowledge of the interplay between formulation and stability that in turn could potentially make formulation development faster, cheaper and less labour intensive than the currently used broad screening approach. Understanding the susceptibilities of formulations to protein aggregation and denaturation can reduce the response time to for instance product failure. Few universities in Europe have formulation of biologics as a scientific subject. Consequently, the pharmaceutical industry is forced to train scientists - a challenge for larger companies, and an insurmountable task for smaller companies. Scientists in the field of structural biology, biophysics, protein formulation and stability have formed a consortium to systematically map physicochemical properties of biologics, formulation conditions and protein stability. The main objective of the consortium is to provide a new generation of innovative and entrepreneurial early-stage researchers that will develop methodologies, tools and databases to guide the formulation of robust biologics. The consortium will not only provide an excellent platform to train a new generation of formulation scientists, but also establish avenues for designing new formulation strategies and thereby securing the leading edge of EU expertise.

Coordinator

DANMARKS TEKNISKE UNIVERSITET

Address

Anker Engelundsvej 1 Bygning 101 A
2800 Kgs Lyngby

Denmark

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 580 163,76

Participants (7)

THE UNIVERSITY OF MANCHESTER

United Kingdom

EU Contribution

€ 546 575,76

LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN

Germany

EU Contribution

€ 747 649,44

LUNDS UNIVERSITET

Sweden

EU Contribution

€ 527 318,64

NOVOZYMES A/S

Denmark

EU Contribution

€ 580 163,76

WYATT TECHNOLOGY EUROPE GMBH

Germany

EU Contribution

€ 249 216,48

MEDIMMUNE LIMITED

United Kingdom

EU Contribution

€ 546 575,76

KOBENHAVNS UNIVERSITET

Denmark

EU Contribution

€ 290 081,88

Partners (2)

LUNDS UNIVERSITET

Sweden

NANOTEMPER TECHNOLOGIES GMBH

Germany

Project information

Grant agreement ID: 675074

Status

Closed project

  • Start date

    1 January 2016

  • End date

    31 December 2019

Funded under:

H2020-EU.1.3.1.

  • Overall budget:

    € 4 067 745,48

  • EU contribution

    € 4 067 745,48

Coordinated by:

DANMARKS TEKNISKE UNIVERSITET

Denmark